Unknown

Dataset Information

0

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.


ABSTRACT: GOG 152 was a randomized trial of secondary cytoreductive surgery (SCS) in patients with suboptimal residual disease (residual tumor nodule >1cm in greatest diameter) following primary cytoreductive surgery for advanced stage ovarian cancer. The current analysis was undertaken to evaluate the impact of disease findings at SCS on progression-free survival (PFS) and overall survival (OS).Among the 550 patients enrolled on GOG-152, two-hundred-sixteen patients were randomly assigned following 3cycles of cisplatin and paclitaxel to receive SCS. In 15 patients (7%) surgery was declined or contraindicated. In the remaining 201 patients the operative and pathology reports were utilized to classify their disease status at the beginning of SCS as; no gross disease/microscopically negative N=40 (19.9%), no gross disease/microscopically positive N=8 (4.0%), and gross disease N=153 (76.1%).The median PFS for patients with no gross disease/microscopically negative was 16.1months, no gross disease/microscopically positive was 13.5months and for gross disease was 11.7months, P=0.002. The median OS for patients with no gross disease/microscopically negative was 51.5months, no gross disease/microscopically positive was 42.6months and for gross disease was 34.9months, P=0.018.Although as previously reported SCS did not change PFS or OS, for those who underwent the procedure, their operative and pathologic findings were predictive of PFS and OS. Surgical/pathological residual disease is a biomarker of response to chemotherapy and predictive of PFS and OS.

SUBMITTER: Rose PG 

PROVIDER: S-EPMC5720165 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Rose Peter G PG   Java James J JJ   Morgan Mark A MA   Alvarez-Secord Angeles A   Kesterson Joshua P JP   Stehman Frederick B FB   Warshal David P DP   Creasman William T WT   Hanjani Parviz P   Morris Robert T RT   Copeland Larry J LJ  

Gynecologic oncology 20160928 3


<h4>Purpose</h4>GOG 152 was a randomized trial of secondary cytoreductive surgery (SCS) in patients with suboptimal residual disease (residual tumor nodule >1cm in greatest diameter) following primary cytoreductive surgery for advanced stage ovarian cancer. The current analysis was undertaken to evaluate the impact of disease findings at SCS on progression-free survival (PFS) and overall survival (OS).<h4>Methods</h4>Among the 550 patients enrolled on GOG-152, two-hundred-sixteen patients were r  ...[more]

Similar Datasets

| S-EPMC7789907 | biostudies-literature
| S-EPMC5339038 | biostudies-other
| S-EPMC4836803 | biostudies-other
| S-EPMC5962447 | biostudies-literature
| S-EPMC5570471 | biostudies-literature
| S-EPMC6544459 | biostudies-literature
| S-EPMC5706110 | biostudies-literature
| S-EPMC5705948 | biostudies-literature
| S-EPMC5815909 | biostudies-literature
| S-EPMC4684156 | biostudies-literature